News
GBT
68.49
0.00%
0.00
FACTBOX-How Pfizer is fortifying for growth beyond COVID products
Pfizer forecast revenue from its COVID-19 vaccine and treatment to be $8 billion in 2024, down from $57 billion in 2022. The company has turned to multi-billion deals, internal restructuring and a massive cost-cutting program. Pfizer is facing a steep fall in demand for its products.
Reuters · 12/13/2023 18:35
BUZZ-Syros Pharmaceuticals drops as Pfizer terminates license deal
Reuters · 07/21/2023 21:07
More
Webull provides a variety of real-time GBT stock news. You can receive the latest news about Global Blood through multiple platforms. This information may help you make smarter investment decisions.
About GBT
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.